Benvenisty, NissimNissimBenvenistyDraper, Jonathan S.Jonathan S.DraperGokhale, Paul J.Paul J.GokhaleHealy, Lyn E.Lyn E.HealyHewitt, Zöe A.Zöe A.HewittHursh, DeborahDeborahHurshHodgson, AdamAdamHodgsonLudwig, Tenneille E.Tenneille E.LudwigMah, Nancy LynneNancy LynneMahMcClelland, Sarah ElizabethSarah ElizabethMcClellandMennecozzi, MilenaMilenaMennecozziMerkle, Florian T.Florian T.MerkleMountford, Joanne C.Joanne C.MountfordPera, Martin F.Martin F.PeraPrigione, A.A.PrigioneRodríguez, Tristan ArgeoTristan ArgeoRodríguezRossi, AndreaAndreaRossiRouhani, Foad J.Foad J.RouhaniSaeb-Parsy, KouroshKouroshSaeb-ParsySelfa Aspiroz, LuciaLuciaSelfa AspirozShakiba, NikaNikaShakibaSpits, ClaudiaClaudiaSpitsTonge, Peter DennisPeter DennisTongeBarbaric, IvanaIvanaBarbaric2025-04-162025-04-162025https://publica.fraunhofer.de/handle/publica/48669810.1016/j.stem.2025.03.003s2.0-105001036627Human pluripotent stem cell (hPSC)-based therapies offer promise but pose potential risks due to culture-acquired genetic variants, some of which have been linked with cancer. An international workshop addressed these concerns, highlighting the need for improved strategies to stratify variants and chart a path toward definitive guidelines in hPSC-based therapy.enfalsenote